Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
CAS Number:
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
MDL number:
Assay:
≥95% (HPLC)
Form:
solid
Quality Level
assay
≥95% (HPLC)
form
solid
storage temp.
−20°C
SMILES string
CC[C@H](C)[C@H](NC(=O)[C@H]([C@@H](C)CC)N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
InChI
1S/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-22(18(7)33)26(37)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,33H,11-14H2,1-10H3,(H,29,37)(H,30,38)(H,31,36)/t16-,17-,18+,20-,21-,22-,23-,28+/m0/s1
InChI key
DOGIDQKFVLKMLQ-JTHVHQAWSA-N
General description
Epoxomicin is a linear peptide consisting of a threonine or serine residue with α′, β′-epoxyketone derived from leucine or a γ,δ-dehydroleucine. It is a natural product isolated from Actinomyces sp., and is a cell-permeable, potent, selective and irreversible proteasome inhibitor.
Application
Epoxomicin has been used:
- as an ubiquitin–proteosome system (UPS) inhibitor in pheochromocytoma PC12 cells
- as a proteasome inhibitor in mammary epithelial MCF-10A cells
- as a proteasome inhibitor in chymotryptic assay in cardiomyocytes
Biochem/physiol Actions
Epoxomicin, a natural product isolated from Actinomyces sp., is a cell-permeable, potent, selective and irreversible proteasome inhibitor.
Epoxomicin binds covalently to the catalytic subunits of proteasome. It forms an adduct with target proteins. It inhibits chymotrypsin-like activity of the proteasome. Epoxomicin also inhibits the nuclear factor κ light chain enhancer of activated B cells (NF-κB) mediated proinflammatory signalling pathway. It is also a potent antitumor and anti-inflammatory agent.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Datasheet
Kyung Bo Kim et al.
Natural product reports, 30(5), 600-604 (2013-04-12)
The initial enthusiasm following the discovery of a pharmacologically active natural product is often fleeting due to the poor prospects for its ultimate clinical application. Despite this, the ever-changing landscape of modern biology has a constant need for molecular probes
Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model
Yu X, et al.
Journal of Molecular Neuroscience, 47(2), 219-233 (2012)
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng L, et al.
Proceedings of the National Academy of Sciences of the USA, 96(18), 10403-10408 (1999)